Document is current
Any future updates will be listed below
-
Authors
Wiest, Isabella Catharina
Ferber, Dyke
Zhu, Jiefu
van Treeck, Marko
Meyer, Sonja K.
Juglan, Radhika
Carrero, Zunamys I. https://orcid.org/0000-0001-8501-1566
Paech, Daniel
Kleesiek, Jens https://orcid.org/0000-0001-8686-0682
Ebert, Matthias P.
Truhn, Daniel https://orcid.org/0000-0002-9605-0728
Kather, Jakob Nikolas https://orcid.org/0000-0002-3730-5348
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (101057091)
- License Information
-
More Information
Article History
Received: 9 January 2024
Accepted: 19 August 2024
First Online: 20 September 2024
Competing interests
: J.N.K. declares consulting services for Bioptimus, France; Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK; AstraZeneca, UK; Scailyte, Switzerland; Mindpeak, Germany; and MultiplexDx, Slovakia. Furthermore he holds shares in StratifAI GmbH, Germany, has received a research grant by GSK, and has received honoraria by AstraZeneca, Bayer, Eisai, Janssen, MSD, BMS, Roche, Pfizer and Fresenius. D.T. has received honoraria for lectures for Bayer and holds shares in StratifAI GmbH, Dresden, Germany. I.C.W. received honoraria from AstraZeneca. The authors have no other financial or non-financial conflicts of interest to disclose. D.F., J.Z., M.T., S.M., R.J., Z.I.C., D.P., J.K. and M.P.E. have no competing interests to declare.
